Trials / Completed
CompletedNCT05222399
A Study of LY3871801 in Healthy Participants
Pharmacokinetics of LY3871801 Following Oral Administration of a Crystalline Freebase Tablet and a Solid Dispersion Oral Suspension
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) and as a solid dispersion oral suspension (reference) in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 15 days excluding the 28 days of screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3871801 | Administered orally. |
Timeline
- Start date
- 2022-02-04
- Primary completion
- 2022-03-11
- Completion
- 2022-03-11
- First posted
- 2022-02-03
- Last updated
- 2022-03-18
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05222399. Inclusion in this directory is not an endorsement.